Search
165 studies match these filters. Showing 76–100 of 165 studies
| Registration number | Study | Status | Phase | Enrolment | Sites / countries | Start year | Last updated | Actions |
|---|---|---|---|---|---|---|---|---|
| NCT07136012 | OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events The primary objective is to evaluate the effect of olpasiran, compared to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants at risk for a first major cardiovascular event with elevated lipoprotein(a) (Lp\[a\]). ✓ Contact✗ Claimed Nearest site: Hutchinson, Kansas, United States — 36 km away · 252 sites in total | Recruiting | Phase 3 | 11,000target | 252 / 3 | 2025 | Aug 21, 2026 | |
| NCT07645924 | A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine This is a double-blind, randomized, multicenter, outpatient evaluation of the efficacy, safety, and tolerability of elismetrep, as compared with placebo, in the acute treatment of migraine. ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 113 sites in total · contact listed | Recruiting | Phase 3 | 1,800target | 113 / 1 | 2026 | Aug 20, 2026 | |
| NCT07097142 | Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study This phase III trial compares the effect of decreased number of radiation (ultra-hypofractionated) treatments to the usual radiation number of treatments (hypofractionation) with standard of care chemotherapy, with cisplatin, gemcitabine or mitomycin and 5-fluorouracil for the treatment of patients… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 211 sites in total · contact listed | Recruiting | Phase 3 | 486target | 211 / 1 | 2025 | Aug 18, 2026 | |
| NCT07567001 | A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo. The purpose of this clinical study is to fi… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 838 sites in total | Recruiting | Phase 3 | 5,610target | 838 / 27 | 2026 | Aug 18, 2026 | |
| NCT05624996 | Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by immunotherapy with durvalumab or targeted therapy with osimertinib) versus the usual treatment alone… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 477 sites in total · contact listed | Recruiting | Phase 3 | 474target | 477 / 2 | 2023 | Aug 17, 2026 | |
| NCT07764978 | Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of standard induction regimens (IsaVRd and DRd) followed by AZD0120 versus standard induction regimens followed by continuous therapy (IsaRd and DRd) in participants with newly diagnos… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 124 sites in total | Recruiting | Phase 3 | 750target | 124 / 15 | 2026 | Aug 14, 2026 | |
| NCT06297291 | Global Paradise System US Post Approval Study The objective of the Global Paradise® System US Post Approval Study (US GPS) is to evaluate the real-world use of the Paradise Ultrasound Renal Denervation System indicated for patients who are unable to lower their blood pressure with lifestyle changes and medication. This system is comprised of a… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 43 sites in total · contact listed | Recruiting | 1,000target | 43 / 1 | 2024 | Aug 12, 2026 | ||
| NCT06880055 | Shield Post-Approval Study Protocol The Shield post-approval study (PAS) is a prospective, longitudinal study supplemented with Real World Evidence (RWE) to evaluate the longitudinal performance of Shield in an average risk population at a second round of testing for individuals between the ages of 45 and 81 at average risk of CRC usi… ✓ Contact✗ Claimed Nearest site: Hutchinson, Kansas, United States — 36 km away · 69 sites in total | Recruiting | 3,375target | 69 / 1 | 2025 | Aug 7, 2026 | ||
| NCT06215716 | A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with non-cirrhotic NASH/MASH and fibrosis stage 2 or 3 (F2 or F3). The study will enroll subjects in two cohorts for a total samples size of 1650 subjects. ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 356 sites in total | Recruiting | Phase 3 | 1,650target | 356 / 18 | 2023 | Aug 7, 2026 | |
| NCT06571669 | BOOM-IBD2 Pivotal Clinical Trial Ulcerative colitis is a long-lasting condition that causes swelling and sores in the large intestine. This study tests whether a small device placed under the skin can help reduce bowel urgency in people with ulcerative colitis. The investigational device sends mild signals to a nerve near the tailb… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 19 sites in total · contact listed | Recruiting | Not applicable | 137target | 19 / 1 | 2025 | Aug 6, 2026 | |
| NCT05812807 | Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab This phase III trial compares the effect of continuation of treatment with pembrolizumab (usual approach) to observation only at preventing cancer from coming back in patients with early-stage triple-negative breast cancer (TNBC) who achieved a pathologic complete response after preoperative chemoth… ✓ Contact✗ Claimed Nearest site: Kingman, Kansas, United States — 28 km away · 846 sites in total · contact listed | Recruiting | Phase 3 | 1,295target | 846 / 3 | 2023 | Aug 5, 2026 | |
| NCT06588855 | A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis This Phase III, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of induction therapy with Afimkibart (RO7790121) compared with placebo in participants with moderately to severely active ulcerative colitis (UC). ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 200 sites in total | Recruiting | Phase 3 | 350target | 200 / 30 | 2024 | Aug 5, 2026 | |
| NCT04267848 | Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immun… ✓ Contact✗ Claimed Nearest site: Kingman, Kansas, United States — 28 km away · 1,151 sites in total | Recruiting | Phase 3 | 1,210target | 1,151 / 2 | 2020 | Sep 23, 2026 | |
| NCT06982521 | Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutation following recurrence or progression on or after treatment… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 231 sites in total | Recruiting | Phase 3 | 540target | 231 / 24 | 2025 | Sep 3, 2026 | |
| NCT06547489 | Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder The goal of this clinical trial is to learn if zelquistinel works to treat depression in adults. It will also learn about the safety of zelquistinel. The main questions it aims to answer are: Does zelquistinel reduce depression scores in participants compared to participants who take a placebo (a l… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 34 sites in total | Recruiting | Phase 2 | 164target | 34 / 1 | 2025 | Aug 3, 2026 | |
| NCT07610278 | A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia This is a multicenter, randomized, double-blind, factorial design Phase 2 study to evaluate the pharmacodynamics, safety and tolerability of a combination of QCZ484 and inclisiran compared to QCZ484, inclisiran, and placebo in participants with hypertension and concomitant hypercholesterolemia. ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 29 sites in total · contact listed | Recruiting | Phase 2 | 120target | 29 / 1 | 2026 | Jul 30, 2026 | |
| NCT07543120 | An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients. The purpose of this extension study is to collect additional safety and efficacy on QCZ484 for hypertensive patients who successfully completed the parent study, CQCZ484A12201 or additional QCZ484 studies as specified in the respective parent study protocols. ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 25 sites in total · contact listed | Recruiting | Phase 2 | 323target | 25 / 3 | 2026 | Jul 30, 2026 | |
| NCT05268289 | Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment. ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 103 sites in total · contact listed | Recruiting | Phase 2 | 240target | 103 / 20 | 2022 | Jul 30, 2026 | |
| NCT06915233 | A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle The objective of this study is to demonstrate the superiority of MACI (autologous cultured chondrocytes on porcine collagen membrane) versus Bone Marrow Stimulation in the treatment of patients aged 17 to 65 years with symptomatic articular chondral or osteochondral defects of the talus. ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 7 sites in total · contact listed | Recruiting | Phase 3 | 309target | 7 / 1 | 2026 | Jul 23, 2026 | |
| NCT07045194 | Virtue® SAB in the Treatment of Coronary ISR Trial A prospective, multi-center, single-blind, randomized (1:1), non-inferiority study comparing clinical outcomes of the Virtue® Sirolimus AngioInfusion™ Balloon (SAB) to the AGENT™ Paclitaxel Drug-Coated Balloon (DCB) in the treatment of coronary artery in-stent restenosis (ISR). ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 15 sites in total · contact listed | Recruiting | Not applicable | 740target | 15 / 1 | 2025 | Jul 23, 2026 | |
| NCT06932263 | Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids This is a dose-range finding, double-blind, placebo-controlled, phase IIb study designed to assess efficacy and safety of tozorakimab administered subcutaneously in adult participants with uncontrolled asthma receiving medium-to-high dose inhaled corticosteroids. ✓ Contact✗ Claimed Nearest site: Hutchinson, Kansas, United States — 36 km away · 221 sites in total | Recruiting | Phase 2 | 540target | 221 / 21 | 2025 | Jul 20, 2026 | |
| NCT05946629 | SELUTION 4 De Novo Small Vessel IDE Trial Prospective, randomized controlled, single-blind, multicenter, clinical trial to demonstrate the safety and efficacy of the SELUTION SLR 014 PTCA DEB for treatment of de novo lesions in small coronary vessels, defined as reference vessel diameter (RVD) of 2.00 mm to 2.75 mm, in support of a pre-mark… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 70 sites in total · contact listed | Recruiting | Not applicable | 960target | 70 / 2 | 2023 | Jul 16, 2026 | |
| NCT06937177 | Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy This is a randomized, double-blind, placebo-controlled basket trial evaluating mifomelatide (TCMCB07) administered daily by subcutaneous (SC) injection in up to 120 patients. Patients will be enrolled into two cohorts 1) patients with newly diagnosed, advanced, unresectable colorectal cancer (CRC) o… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 26 sites in total · contact listed | Recruiting | Phase 2 | 120target | 26 / 2 | 2025 | Jul 15, 2026 | |
| NCT05712200 | Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76) A study to evaluate the effect of abelacimab relative to placebo on the rate of ischemic stroke or systemic embolism (SE) in patients with Atrial Fibrillation (AF) who have been deemed by their responsible physicians or by their own decision to be unsuitable for oral anticoagulation therapy. ✓ Contact✗ Claimed Nearest site: Hutchinson, Kansas, United States — 36 km away · 789 sites in total · contact listed | Recruiting | Phase 3 | 2,500target | 789 / 35 | 2022 | Jul 13, 2026 | |
| NCT06582810 | Lidocaine Infusion Treatment for Subarachnoid Hemorrhage Headaches The goal of this observational study is to evaluate intravenous lidocaine efficacy and safety in treating headache following non-traumatic subarachnoid hemorrhage. Through this prospective analysis, the investigators hope to: 1. show that intravenous lidocaine infusion causes a clinically significa… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · contact listed | Recruiting | 20target | 1 / 1 | 2025 | Jul 10, 2026 |